Skip to main content
Premium Trial:

Request an Annual Quote

TwinStrand Biosciences Raises $50M in Series B Round

NEW YORK — TwinStrand Biosciences said on Thursday that it has raised $50 million in a Series B financing round.

The round was led by Section 32 and included existing investors Madrona Venture Group, Ridgeback Capital, and Alexandria Venture Investments, as well as new investors Soleus Capital and Janus Henderson Investors. In conjunction with the financing, Section 32 partner Michael Pellini, the former CEO and chairman of Foundation Medicine, has joined TwinStrand's board of directors.

TwinStrand was spun out of the University of Washington to commercialize an error-reducing duplex sequencing technology that the company says can identify ultra-low frequency genomic variants that are undetectable with other methods.

In early 2020, the company commercialized its first products based on the technology: research-use kits for minimal residual disease detection in acute myeloid leukemia and for identifying carcinogens through genetic toxicology assays. Around that time it also raised $16 million in a Series A round.

Later that year, it nonexclusively licensed the technology to Roche's Foundation Medicine, which has since incorporated it into its tumor profiling assays.

Since then, Seattle-based TwinStrand had been working to validate the technology through a research partnership with academic groups and pharmaceutical companies while laying out plans to double its workforce to around 80 employees by the end of 2021.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.